Literature DB >> 23433867

Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection.

D N Shah1, N S Bhatt, J K Welch, H L Koo, K W Garey.   

Abstract

BACKGROUND: Acute renal dysfunction can be used to define severe Clostridium difficile infection (CDI). The Society for Healthcare Epidemiology of America (SHEA) and Infectious Disease Society of America (IDSA) guidelines define acute renal dysfunction as serum creatinine (SrCr) ≥1.5 times the premorbid level. AIM: To determine the ability to assess premorbid SrCr in hospitalized patients with CDI, stratified into community-onset CDI (CO-CDI) and hospital-onset CDI (HO-CDI); and to evaluate differing definitions for premorbid SrCr as a criterion for acute renal dysfunction.
METHODS: Hospitalized patients with CDI were stratified into CO-CDI and HO-CDI. The ability to assess premorbid SrCr was determined, and the incidence of acute renal dysfunction and the severity of CDI were compared using varying definitions of premorbid SrCr.
FINDINGS: In total, 293 patients with CDI were evaluated; of these, 135 (46%) had CO-CDI and 158 (54%) had HO-CDI. Premorbid SrCr data were not available for 37 (27%) patients with CO-CDI and one (<1%) patient with HO-CDI (P < 0.0001). Depending on the definition of premorbid SrCr used, acute renal dysfunction ranged from 17% to 24% for patients with CO-CDI (P = 0.26), and from 13% to 14% for HO-CDI (P = 0.81). The severity of CDI could not be determined for 43 out of 293 (15%) patients, primarily due to the lack of premorbid SrCr data (N = 38).
CONCLUSION: Assessment of acute renal dysfunction and the severity of CDI was not possible for many patients with CO-CDI using the current SHEA/IDSA guidelines. Given the increasing incidence of CO-CDI, an alternative definition of acute renal dysfunction may be required.
Copyright © 2013 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23433867      PMCID: PMC3984400          DOI: 10.1016/j.jhin.2012.12.011

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  20 in total

1.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

2.  Predictors of serious complications due to Clostridium difficile infection.

Authors:  D Gujja; F K Friedenberg
Journal:  Aliment Pharmacol Ther       Date:  2008-12-10       Impact factor: 8.171

3.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

Authors:  M P Bauer; E J Kuijper; J T van Dissel
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

4.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

5.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

6.  Clostridium difficile-associated diarrhea and chronic renal insufficiency.

Authors:  Khurshid Yousuf; Mohammad G Saklayen; Ronald J Markert; Christopher J Barde; Narasimh Gopalswamy
Journal:  South Med J       Date:  2002-07       Impact factor: 0.954

7.  Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile.

Authors:  J Bishara; N Peled; S Pitlik; Z Samra
Journal:  J Hosp Infect       Date:  2008-03-19       Impact factor: 3.926

8.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

9.  Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients.

Authors:  F Barbut; C Depitre; M Delmée; G Corthier; J C Petit
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

10.  Clinical risk factors for severe Clostridium difficile-associated disease.

Authors:  Timothy J Henrich; Douglas Krakower; Asaf Bitton; Deborah S Yokoe
Journal:  Emerg Infect Dis       Date:  2009-03       Impact factor: 6.883

View more
  7 in total

1.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

2.  Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study.

Authors:  Ronza Najjar-Debbiny; Alina Bazazhina; Naama Schwartz; Pninit Shaked; Walid Saliba; Gabriel Weber
Journal:  Infection       Date:  2022-02-22       Impact factor: 7.455

3.  Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection.

Authors:  Travis J Carlson; Anne J Gonzales-Luna; Kimberly Nebo; Hannah Y Chan; Ngoc-Linh T Tran; Sheena Antony; Chris Lancaster; M Jahangir Alam; Khurshida Begum; Kevin W Garey
Journal:  Open Forum Infect Dis       Date:  2020-10-07       Impact factor: 3.835

4.  In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent.

Authors:  Samuel L Aitken; M Jahangir Alam; Mohammed Khaleduzzaman; Mohammed Khaleduzzuman; Seth T Walk; William L Musick; Vy P Pham; Jennifer L Christensen; Robert L Atmar; Yang Xie; Kevin W Garey
Journal:  Infect Control Hosp Epidemiol       Date:  2015-08-20       Impact factor: 3.254

5.  A multi-center study of fidaxomicin use for Clostridium difficile infection.

Authors:  Dhara N Shah; Fay S Chan; Nandita Kachru; Krutina P Garcia; Holly E Balcer; April P Dyer; John E Emanuel; Michelle D Jordan; Katherine T Lusardi; Geri Naymick; Radhika S Polisetty; Lanny Sieman; Ashley M Tyler; Michael L Johnson; Kevin W Garey
Journal:  Springerplus       Date:  2016-08-02

6.  Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea.

Authors:  Jaeuk Shin; Yu Mi Wi; Yu-Ji Lee
Journal:  Epidemiol Infect       Date:  2019-10-14       Impact factor: 2.451

Review 7.  zzm321990 Clostridioides difficile Infection, Still a Long Way to Go.

Authors:  Eleftheria Kampouri; Antony Croxatto; Guy Prod'hom; Benoit Guery
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.